research use only
Cat.No.E1971
|
In vitro |
DMSO
: 100 mg/mL
(183.29 mM)
Ethanol : 25 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 545.57 | Formula | C28H31F4N5O2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 2636846-41-6 | Download SDF | Storage of Stock Solutions |
|
|
Read more about storage stability stock solution CAS number
| Targets/IC50/Ki |
p53
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2026-08-20)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06616636 | RECRUITING | Myelodysplastic Syndrome; Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2025-01-30 | PHASE1 |
| NCT07372625 | RECRUITING | TP53 Y220C Mutation; Advanced Solid Tumors |
PMV Pharmaceuticals, Inc |
2026-02-04 | PHASE1 |
| NCT04585750 | RECRUITING | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Cancer; Ovarian Cancer; Endometrial Cancer; Prostate Cancer; Colorectal Cancer; Breast Cancer; Other Cancer; Locally Advanced; Head and Neck Cancer; Gall Bladder Cancer; Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); Small Cell Lung Carcinoma; NSCLC; NSCLC (Non-small Cell Lung Cancer); SCLC; Non-Small Cell Lung Carcinoma; Triple Negative Breast Cancer; TNBC; HER2+ Breast Cancer; Non-Small Cell Lung Cancer; ER/PR Positive Breast Cancer; HER2- Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; ER/PR(+), Her2(-) Breast Cancer |
PMV Pharmaceuticals, Inc |
2020-10-29 | PHASE1; PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.